design: estrogen plus progestin component of the women's health initiative, a randomized controlled primary prevention trial (planned duration, 8.5 years) in which 16608 postmenopausal women aged 50-79 years with an intact uterus at baseline were recruited by 40 us clinical centers in 1993-1998.